» Articles » PMID: 36224199

Differential ABC Transporter Expression During Hematopoiesis Contributes to Neutrophil-biased Toxicity of Aurora Kinase Inhibitors

Abstract

Drug-induced cytopenias are a prevalent and significant issue that worsens clinical outcomes and hinders the effective treatment of cancer. While reductions in blood cell numbers are classically associated with traditional cytotoxic chemotherapies, they also occur with newer targeted small molecules and the factors that determine the hematotoxicity profiles of oncologic drugs are not fully understood. Here, we explore why some Aurora kinase inhibitors cause preferential neutropenia. By studying drug responses of healthy human hematopoietic cells in vitro and analyzing existing gene expression datasets, we provide evidence that the enhanced vulnerability of neutrophil-lineage cells to Aurora kinase inhibition is caused by early developmental changes in ATP-binding cassette (ABC) transporter expression. These data show that hematopoietic cell-intrinsic expression of ABC transporters may be an important factor that determines how some Aurora kinase inhibitors affect the bone marrow.

Citing Articles

Human organ chips for regenerative pharmacology.

Goyal G, Belgur C, Ingber D Pharmacol Res Perspect. 2023; 12(1):e01159.

PMID: 38149766 PMC: 10751726. DOI: 10.1002/prp2.1159.


ABCC4 impacts megakaryopoiesis and protects megakaryocytes against 6-mercaptopurine induced cytotoxicity.

Ranjit S, Wang Y, Zhu J, Cheepala S, Schuetz E, Cho W Drug Resist Updat. 2023; 72:101017.

PMID: 37988981 PMC: 10874622. DOI: 10.1016/j.drup.2023.101017.

References
1.
Repetto L . Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol. 2009; 72(2):170-9. DOI: 10.1016/j.critrevonc.2009.03.004. View

2.
Schinkel A, Smit J, van Tellingen O, Beijnen J, Wagenaar E, van Deemter L . Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77(4):491-502. DOI: 10.1016/0092-8674(94)90212-7. View

3.
Borisa A, Bhatt H . A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. Eur J Med Chem. 2017; 140:1-19. DOI: 10.1016/j.ejmech.2017.08.045. View

4.
Borthakur G, Dombret H, Schafhausen P, Brummendorf T, Boissel N, Jabbour E . A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second.... Haematologica. 2015; 100(7):898-904. PMC: 4486224. DOI: 10.3324/haematol.2014.115279. View

5.
Hassan M, Brown R, Varma-Obrien S, Rogers D . Cheminformatics analysis and learning in a data pipelining environment. Mol Divers. 2006; 10(3):283-99. DOI: 10.1007/s11030-006-9041-5. View